Articles From: UPDATE: 5 key points in J.P. Morgan earnings to Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy


2014/10/14
By Sital S.
Sign-up for UPDATE: 5 key points in J.P. Morgan earnings investment picks
2014/10/14
By Sital S.
Sign-up for UPDATE: 5 things to note in J.P. Morgan earnings investment picks
2014/10/14
By Sital S.
Sign-up for 5 things to note in J.P. Morgan earnings investment picks
2014/10/14
By Sital S.
Sign-up for UPDATE: What to watch for in Citigroup earnings investment picks
2014/10/21
By Sital S.
Sign-up for UPDATE: What to watch for in Coca-Cola earnings investment picks
2014/10/24
By Sital S.
Sign-up for UPDATE: Wells Fargo CEO defends bank's pay model investment picks
2014/10/23
By Sital S.
Sign-up for UPDATE: Wells Fargo CEO defends bank's pay model investment picks
2014/10/23
By Sital S.
Sign-up for Wells Fargo CEO defends bank's pay model investment picks
2014/11/5
By Sital S.
Sign-up for Consolation prize for ousted politicians: Bigger salaries in the private sector investment picks
2014/11/3
By Sital S.
Sign-up for UPDATE: What to watch for in Alibaba earnings investment picks
2014/11/3
By Sital S.
Sign-up for What to watch for in Alibaba earnings investment picks
2014/10/31
By Sital S.
Sign-up for UPDATE: What to watch for in AIG earnings investment picks
2014/10/30
By Sital S.
Sign-up for UPDATE: Analysts cheer Visa's better-than-expected quarter, shares rally 9% investment picks
2014/10/30
By Sital S.
Sign-up for UPDATE: What to watch for in GoPro earnings investment picks
2014/10/29
By Sital S.
Sign-up for What to watch for in GoPro earnings investment picks
2014/10/28
By Sital S.
Sign-up for What to watch for in Visa earnings investment picks
2014/11/13
By Sital S.
Sign-up for UPDATE: Duracell deal is a typical Warren Buffett play -- a bargain investment picks
2014/11/13
By Sital S.
Sign-up for Duracell deal is a typical Warren Buffett play -- at a discount investment picks
2014/11/12
By Sital S.
Sign-up for UPDATE: BB&T- Susquehanna merger hinges on regulators investment picks
2014/11/12
By Sital S.
Sign-up for BB&T- Susquehanna merger hinges on regulators investment picks
2014/11/11
By Sital S.
Sign-up for UPDATE: Attorney general nominee Lynch expected to keep tabs on Wall Street investment picks
By Sital S.
Sign-up for UPDATE: Why Apple Pay will change your spending habits forever investment picks
By Sital S.
Sign-up for UPDATE: Financial stocks lead market slump investment picks
By Sital S.
Sign-up for UPDATE: Costco ditches Amex at its Canadian stores investment picks
By Sital S.
Sign-up for Financial stocks lead market slump investment picks
By Sital S.
Sign-up for UPDATE: Financial stocks lead market rout investment picks
Sarepta Therapeutics, Inc. (NASDAQ:SRPT), a developer of innovative RNA-based therapeutics, today provided an update on its discussions with the U.S. Food and Drug Administration (FDA) regarding its planned New Drug Application (NDA) submission for the approval of eteplirsen for the treatment of Duchenne muscular dystrophy (DMD). In meeting minutes received last week from a Type B Pre-NDA meeting that took place in September 2014, the FDA provided updated guidance regarding the specific data to be included as part of, or at the time of, Sarepta’s NDA submission.
Sign-up for Sarepta Therapeutics Announces Regulatory Update on Eteplirsen investment picks
Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of RNA-based therapeutics, today announced that it has initiated dosing in a clinical study of eteplirsen, the Company's lead exon-skipping therapeutic candidate for the treatment of Duchenne muscular dystrophy (DMD), in patients who are non-ambulant or who have advanced DMD and don't meet a minimum 6-minute walk test score at baseline.
Sign-up for Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy investment picks
Go Premium!
Exclusive Premium Member Benefits
Get the best thinking of 150+ disciplined
objective, experienced analysts-dedicated to
specific industries and securities.
+2,500 Analyst Reports
Wide Moat Screener for Stocks
Medalist Screener for Funds
Premium Portfolio Manager with X-Ray & Monitor
Premium eNewsletters
Morningstar Basic Benefits (All)
Sign up now - No charge for the first 14 days
Articles From: UPDATE: 5 key points in J.P. Morgan earnings to Sarepta Therapeutics Announces First Patient Dosed in Study of Eteplirsen in Non-Ambulant Patients with Duchenne Muscular Dystrophy
Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol |  Title Star Rating |  Category |  Total Assets |  Top Holdings |  Top Sectors |  Symbol |  Name Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Star Rating |  Market Cap |  Stock Type |  Sector |  Industry Star Rating |  Investment Style |  Total Assets |  Category |  Top Holdings |  Top Sectors |  Symbol / Ticker |  Title Star Rating |  Category |  Total Assets |  Symbol / Ticker |  Name Title |  Date |  Author |  Collection |  Popularity |  Interest Title |  Date |  Company |  Symbol |  Interest |  Popularity Title |  Date |  Company |  Symbol |  Interest |  Popularity Topic |  Sector |  Key Indicators |  User Interest |  Market Cap |  Industry Name |  Ticker |  Popularity |  Our Choices |  Most Recent